Publications by authors named "Jonathan Visentin"

157 Publications

Characterization of the novel HLA-DQB1*02:197 allele by sequencing-based typing.

HLA 2022 Mar 28. Epub 2022 Mar 28.

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France.

HLA-DQB1*02:197 differs from HLA-DQB1*02:01:01:01 by one nucleotide substitution in codon 18 in exon 2. This article is protected by copyright. All rights reserved.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/tan.14614DOI Listing
March 2022

Characterization of the novel HLA-B*44:03:62 allele by sequencing-based typing.

HLA 2022 Mar 28. Epub 2022 Mar 28.

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.

HLA-B*44:03:62 differs from HLA-B*44:03:01:01 by one nucleotide substitution in codon 127 in exon 3.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/tan.14616DOI Listing
March 2022

The Proteome of Antibody-Mediated Rejection: From Glomerulitis to Transplant Glomerulopathy.

Biomedicines 2022 Feb 28;10(3). Epub 2022 Feb 28.

ImmunoConcEpT, CNRS, Université Bordeaux, UMR 5164, 146 Rue Léo Saignat, F-33000 Bordeaux, France.

Antibody-mediated rejection (ABMR) is the leading cause of allograft failure in kidney transplantation. Its histological hallmark is represented by lesions of glomerulitis i.e., inflammatory cells within glomeruli. Current therapies for ABMR fail to prevent chronic allograft damage i.e., transplant glomerulopathy, leading to allograft loss. We used laser microdissection of glomeruli from formalin-fixed allograft biopsies combined with mass spectrometry-based proteomics to describe the proteome modification of 11 active and 10 chronic active ABMR cases compared to 8 stable graft controls. Of 1335 detected proteins, 77 were deregulated in glomerulitis compared to stable grafts, particularly involved in cellular stress mediated by interferons type I and II, leukocyte activation and microcirculation remodeling. Three proteins extracted from this protein profile, TYMP, WARS1 and GBP1, showed a consistent overexpression by immunohistochemistry in glomerular endothelial cells that may represent relevant markers of endothelial stress during active ABMR. In transplant glomerulopathy, 137 proteins were deregulated, which favor a complement-mediated mechanism, wound healing processes through coagulation activation and ultimately a remodeling of the glomerular extracellular matrix, as observed by light microscopy. This study brings novel information on glomerular proteomics of ABMR in kidney transplantation, and highlights potential targets of diagnostic and therapeutic interest.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3390/biomedicines10030569DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945687PMC
February 2022

Characterization of the novel HLA-C*12:354 allele by sequencing-based typing.

HLA 2022 Mar 8. Epub 2022 Mar 8.

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.

HLA-C*12:354 differs from HLA-C*12:03:01:01 by one nucleotide substitution in codon 240 in exon 4.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/tan.14594DOI Listing
March 2022

Characterization of the novel HLA-B*44:544N allele by sequencing-based typing.

HLA 2022 Feb 13. Epub 2022 Feb 13.

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.

HLA-B*44:544N differs from HLA-B*44:02:01:01 by one nucleotide substitution in codon 147 in exon 3.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/tan.14581DOI Listing
February 2022

Characterization of the novel HLA-A*24:564 allele by sequencing-based typing.

HLA 2022 Feb 4. Epub 2022 Feb 4.

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France.

HLA-A*24:564 differs from HLA-A*24:02:01:01 by one nucleotide substitution in codon 240 in exon 4.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/tan.14576DOI Listing
February 2022

Characterization of the novel HLA-A*03:436 allele by sequencing-based typing.

HLA 2022 Jan 25. Epub 2022 Jan 25.

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.

HLA-A*03:436 differs from HLA-A*03:01:01:05 by one nucleotide substitution in codon 26 in exon 2.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/tan.14565DOI Listing
January 2022

Incidence of cytomegalovirus infection in seropositive kidney transplant recipients treated with everolimus: A randomized, open-label, multicenter phase 4 trial.

Am J Transplant 2022 May 19;22(5):1430-1441. Epub 2022 Jan 19.

Department of Nephrology, Transplantation, Dialysis and Apheresis, CHU Bordeaux, Bordeaux, France.

Cytomegalovirus (CMV) persists as the most frequent opportunistic infection among solid organ transplant recipients. This multicenter trial aimed to test whether treatment with everolimus (EVR) could decrease the incidence of CMV DNAemia and disease. We randomized 186 CMV seropositive kidney transplant recipients in a 1:1 ratio to receive EVR or mycophenolic acid (MPA) in association with basiliximab, cyclosporin, and steroids and 87 in each group were analyzed. No universal prophylaxis was administered to either group. The composite primary endpoint was the presence of CMV DNAemia, CMV treatment, graft loss, death, and discontinuation of the study at 6 months posttransplant. In the modified intent-to-treat analysis, 42 (48.3%) and 70 (80.5%) patients in the EVR and MPA groups reached the primary endpoint (OR = 0.21, 95% CI: 0.11-0.43, p < .0001). Fewer patients of the EVR group received treatment for CMV (21.8% vs. 47.1%, p = .0007). EVR was discontinued in 31 (35.6%) patients. Among the 56 patients with ongoing EVR treatment, only 7.4% received treatment for CMV. In conclusion, EVR prevents CMV DNAemia requiring treatment in seropositive recipients as long as it is tolerated and maintained.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.16946DOI Listing
May 2022

Characterization of the novel HLA-A*30:02:28 allele by sequencing-based typing.

HLA 2022 04 20;99(4):377-378. Epub 2021 Dec 20.

CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, Lille, France.

HLA-A*30:02:28 differs from HLA-A*30:02:01:01 by one nucleotide substitution in codon 47 in exon 2.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/tan.14513DOI Listing
April 2022

IgG3 donor-specific antibodies with a proinflammatory glycosylation profile may be associated with the risk of antibody-mediated rejection after kidney transplantation.

Am J Transplant 2022 03 18;22(3):865-875. Epub 2021 Dec 18.

Department of Nephrology, Dialysis and Transplantation, Montpellier University hospital, Montpellier, France.

The pathogenicity of de novo donor-specific antibodies (dnDSA) varies according to their characteristics. While their MFI, complement-fixing ability, and IgG3 subclass are associated with ABMR occurrence and graft loss, they are not fully predictive of outcomes. We investigated the role of the Fc glycosylation of IgG3 dnDSA in ABMR occurrence using mass spectrometry after isolation by single HLA antigen beads. Between 2014 and 2018, we enrolled 54 patients who developed dnDSA (ABMR- n = 24; ABMR+ n = 30) in two French transplant centers. Fucosylation, galactosylation, GlcNAc bisection, and sialylation of IgG3 dnDSA were compared between ABMR+ and ABMR- patients. IgG3 dnDSA from ABMR+ patients exhibited significantly lower sialylation (7.5% vs. 10.5%, p < .001) and higher GlcNAc bisection (20.6% vs. 17.4%, p = .008). Fucosylation and galactosylation were similar in both groups. DSA glycosylation was not correlated with DSA MFI. In a multivariate analysis, low IgG3 sialylation, high IgG3%, time from transplantation to kidney biopsy, and tacrolimus-free regimen were independent predictive factors of ABMR. We conclude that a proinflammatory glycosylation profile of IgG3 dnDSA is associated with a risk of ABMR occurrence. Further studies are needed to confirm the clinical interest of DSA glycosylation and to clarify its role in determining the risk of ABMR and graft survival.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.16904DOI Listing
March 2022

Characterization of the novel HLA-B*57:146 allele by sequencing-based typing.

HLA 2022 04 1;99(4):389-390. Epub 2021 Dec 1.

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.

HLA-B*57:146 differs from HLA-B*57:01:01:01 by one nucleotide substitution in codon 103 in exon 3.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/tan.14497DOI Listing
April 2022

Characterization of the novel HLA-DQA1*05:49 allele by sequencing-based typing.

HLA 2022 02 2;99(2):140-141. Epub 2021 Dec 2.

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.

HLA-DQA1*05:49 differs from HLA-DQA1*05:01:01:02 by one nucleotide substitution in codon 78 in exon 2.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/tan.14500DOI Listing
February 2022

Characterization of the novel HLA-DQA1*01:76 allele by sequencing-based typing.

HLA 2022 02 3;99(2):136-137. Epub 2021 Dec 3.

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France.

HLA-DQA1*01:76 differs from HLA-DQA1*01:03:01:06 by one nucleotide substitution in codon -11 in exon 1.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/tan.14499DOI Listing
February 2022

Characterization of the novel HLA-DRB4*01:151 allele by sequencing-based typing.

HLA 2022 01 1;99(1):64-66. Epub 2021 Dec 1.

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France.

HLA-DRB4*01:151 differs from DRB4*01:01:01:01 by one nucleotide substitution in codon 178 in exon 3.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/tan.14501DOI Listing
January 2022

Characterization of the novel HLA-DPB1*665:01:02 allele by sequencing-based typing.

HLA 2022 02 2;99(2):150-152. Epub 2021 Dec 2.

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.

HLA-DPB1*665:01:02 differs from HLA-DPB1*665:01:01 by one nucleotide substitution in codon 139 in exon 3.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/tan.14496DOI Listing
February 2022

Characterization of the novel HLA-DQA1*01:02:11 allele by sequencing-based typing.

HLA 2021 12 25;98(6):566-568. Epub 2021 Aug 25.

Laboratoire d'Immunologie et Immunogénétique, CHU de Bordeaux, Hôpital Pellegrin, Bordeaux, France.

HLA-DQA1*01:02:11 differs from HLA-DQA1*01:02:01:10 by one nucleotide substitution in codon 201 in exon 4.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/tan.14394DOI Listing
December 2021

Characterization of the novel HLA-C*07:01:101 allele by sequencing-based typing.

HLA 2021 12 17;98(6):556-557. Epub 2021 Aug 17.

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France.

HLA-C*07:01:101 differs from HLA-C*07:01:01:15 by one nucleotide substitution in codon 332 in exon 7.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/tan.14395DOI Listing
December 2021

Characterization of the novel HLA-B*44:02:73 allele by sequencing-based typing.

HLA 2021 11 17;98(5):474-476. Epub 2021 Aug 17.

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France.

HLA-B*44:02:73 differs from HLA-B*44:02:01:01 by one nucleotide substitution in codon 89 in exon 2.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/tan.14393DOI Listing
November 2021

Characterization of the novel HLA-A*24:538 allele by sequencing-based typing.

HLA 2021 11 17;98(5):473-474. Epub 2021 Aug 17.

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France.

HLA-A*24:538 differs from HLA-A*24:02:01:01 by one nucleotide substitution in codon -21 in exon 1.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/tan.14392DOI Listing
November 2021

Characterization of the novel HLA-DPA1*01:61 allele by sequencing-based typing.

HLA 2021 12 2;98(6):577-578. Epub 2021 Aug 2.

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.

HLA-DPA1*01:61 differs from HLA-DPA1*01:03:01:22 by one nucleotide substitution in codon 96 in exon 3.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/tan.14380DOI Listing
December 2021

Characterization of the novel HLA-C*04:451 allele by sequencing-based typing.

HLA 2021 11 6;98(5):483-485. Epub 2021 Aug 6.

Histocompatibility and Immunogenetics Laboratory, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.

HLA-C*04:451 differs from HLA-C*04:01:01:01 by one nucleotide substitution in codon 229 in exon 4.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/tan.14384DOI Listing
November 2021

Characterization of the novel HLA-DPA1*01:60 allele by sequencing-based typing.

HLA 2021 12 6;98(6):575-576. Epub 2021 Aug 6.

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France.

HLA-DPA1*01:60 differs from HLA-DPA1*01:03:01:04 by one nucleotide substitution in codon 224 in exon 4.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/tan.14378DOI Listing
December 2021

Characterization of the novel HLA-C*15:241 allele by sequencing-based typing.

HLA 2021 10 4;98(4):397-399. Epub 2021 Aug 4.

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, F-33000 Bordeaux, France.

HLA-C*15:241 differs from HLA-C*15:02:01:01 by one nucleotide substitution in codon 48 in exon 2.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/tan.14383DOI Listing
October 2021

Characterization of the novel HLA-C*01:214 allele by sequencing-based typing.

HLA 2021 11 4;98(5):481-483. Epub 2021 Aug 4.

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France.

HLA-C*01:214 differs from HLA-C*01:02:01:01 by one nucleotide substitution in codon -10 in exon 1.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/tan.14381DOI Listing
November 2021

Prospective Measures of Adherence by Questionnaire, Low Immunosuppression and Graft Outcome in Kidney Transplantation.

J Clin Med 2021 May 10;10(9). Epub 2021 May 10.

Service de Néphrologie-Transplantation-Dialyse-Aphérèse, Hôpital Pellegrin, CHU de Bordeaux Pellegrin, 33076 Bordeaux, France.

Background: Non-adherence with immunosuppressant medication (MNA) fosters development of de novo donor-specific antibodies (DSA), rejection, and graft failure (GF) in kidney transplant recipients (KTRs). However, there is no simple tool to assess MNA, prospectively. The goal was to monitor MNA and analyze its predictive value for DSA generation, acute rejection and GF.

Methods: We enrolled 301 KTRs in a multicentric French study. MNA was assessed prospectively at 3, 6, 12, and 24 months (M) post-KT, using the Morisky scale. We investigated the association between MNA and occurrence of DSA at year 2 post transplantation, using logistic regression models and the association between MNA and rejection or graft failure, using Cox multivariable models.

Results: The initial percentage of MNA patients was 17.7%, increasing to 34.6% at 24 months. Nineteen patients (8.4%) developed DSA 2 to 3 years after KT. After adjustment for recipient age, HLA sensitization, HLA mismatches, and maintenance treatment, MNA was associated neither with DSA occurrence, nor acute rejection. Only cyclosporine use and calcineurin inhibitor (CNI) withdrawal were strongly associated with DSA and rejection. With a median follow-up of 8.9 years, GF occurred in 87 patients (29.0%). After adjustment for recipient and donor age, CNI trough level, DSA, and rejection, MNA was not associated with GF. The only parameters associated with GF were DSA occurrence, and acute rejection.

Conclusions: Prospective serial monitoring of MNA using the Morisky scale does not predict DSA occurrence, rejection or GF in KTRs. In contrast, cyclosporine and CNI withdrawal induce dnDSA and rejection, which lead to GF.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm10092032DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125965PMC
May 2021

Stability of Anti-HLA Sensitization Profiles in Highly Sensitized Kidney Transplantation Candidates: Toward a Rational Serological Testing Strategy.

Transplantation 2022 04;106(4):869-878

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France.

Background: Highly sensitized (HS) anti-HLA patients awaiting kidney transplantation benefit from specific allocation programs. Serological monitoring at 3-mo intervals is recommended to prevent unexpected positive crossmatch (XM), but this strategy is not evidence-based. Therefore, we assessed its relevance when using single-antigen flow bead (SAFB) and screening flow bead (SFB) assays.

Methods: We included 166 HS patients awaiting a transplant and assessed their SAFB profile during the year preceding their inclusion. Anti-HLA antibodies were evaluated by SAFB assay and compared within patients as serum pairs at 3, 6, and 9 mo. We assessed the performance of SFB for detecting changes in SAFB profiles with 35 serum pairs.

Results: On comparing 354, 218, and 107 serum pairs at 3, 6, and 9 mo, respectively, only 0.6%, 0.7%, and 1% of all antigens tested exceeded for the first time the unacceptable antigen threshold (mean fluorescence intensity ≥2000) in the most recent sample. Irrespective of the follow-up period, the calculated panel-reactive antibodies increased by a mean of 1%, and there was no significant increase in the proportion of donors at risk for positivity of flow- or complement-dependent cytotoxicity XM. The SFB did not accurately detect the variations of SAFB profiles.

Conclusions: Changes in HS patient profiles are anecdotal and show little association with transplant access or risk for positive XM. Less-frequent monitoring in HS patients should be considered to improve cost-effectiveness without affecting transplant safety.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1097/TP.0000000000003822DOI Listing
April 2022

Identification of the novel HLA-DQB1*05:275 allele by next-generation sequencing.

HLA 2021 12 7;98(6):571-572. Epub 2021 Jun 7.

CHU Toulouse, Laboratoire d'Immunologie, Institut Fédératif de Biologie, Hôpital Purpan, Toulouse, France.

HLA-DQB1*05:275 differs from DQB1*05:01 by one nucleotide substitution in codon 224 in exon 4.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/tan.14310DOI Listing
December 2021

Characterization of the novel HLA-DRB1*11:282 allele by sequencing-based typing.

HLA 2021 08 19;98(2):182-184. Epub 2021 May 19.

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.

HLA-DRB1*11:282 differs from HLA-DRB1*11:04:01:01 by one nucleotide substitution in codon 41 in exon 2.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/tan.14308DOI Listing
August 2021

Characterization of the novel HLA-DQA1*01:58 allele by sequencing-based typing.

HLA 2021 07 18;98(1):76-77. Epub 2021 May 18.

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.

HLA-DQA1*01:58 differs from HLA-DQA1*01:02:01:06 by one nucleotide substitution in codon 46 in exon 2.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/tan.14306DOI Listing
July 2021

Characterization of the novel HLA-A*36:12 allele by sequencing-based typing.

HLA 2021 07 24;98(1):51-53. Epub 2021 May 24.

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.

HLA-A*36:12 differs from HLA-A*36:01:01:01 by one nucleotide substitution in codon 211 in exon 4.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/tan.14296DOI Listing
July 2021
-->